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Abstract
More accurate predictions of the biological properties of chemical compounds
would guide the selection and design of new compounds in drug discovery and
help to address the enormous cost and low success-rate of pharmaceutical R&D.
However, this domain presents a significant challenge for AI methods due to
the sparsity of compound data and the noise inherent in results from biological
experiments. In this paper, we demonstrate how data imputation using deep
learning provides substantial improvements over quantitative structure-activity
relationship (QSAR) machine learning models that are widely applied in drug
discovery. We present the largest-to-date successful application of deep-learning
imputation to datasets which are comparable in size to the corporate data repos-
itory of a pharmaceutical company (678 994 compounds by 1166 endpoints). We
demonstrate this improvement for three areas of practical application linked to
distinct use cases; (a) target activity data compiled from a range of drug discov-
ery projects, (b) a high value and heterogeneous dataset covering complex
absorption, distribution, metabolism, and elimination properties, and (c) high
throughput screening data, testing the algorithm's limits on early stage noisy
and very sparse data. Achieving median coefficients of determination, R2, of
0.69, 0.36, and 0.43, respectively, across these applications, the deep learning
imputation method offers an unambiguous improvement over random forest
QSAR methods, which achieve median R2 values of 0.28, 0.19, and 0.23, respec-
tively. We also demonstrate that robust estimates of the uncertainties in the
predicted values correlate strongly with the accuracies in prediction, enabling
greater confidence in decision-making based on the imputed values.
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INTRODUCTION
The combination of deep learning and statistical imputation methods is seeing rapidly growing success in a wide range
of scientific domains including high-value materials discovery,1,2 the development of new chemicals for industrial
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applications,3,4 battery development,5 and most importantly for the context of this work small molecules drug discov-
ery.6-11 This success can be attributed to the predictive power of the deep learning methodology combined with the flex-
ibility and practical advantages of the imputation framework, which can handle sparse datasets, and use existing,
partial assay data to enhance the quality of predictions for missing values in the dataset.8 Sparse datasets are common
in experimental scientific domains, where it is extremely rare that all possible experiments are run on all possible sub-
jects, often due to the cost and time associated with collecting experimental data.6,8
In this paper, we will focus on applications of deep learning imputation to the discovery of new drugs. This is a par-
ticularly attractive field for the application of artificial intelligence methods of many kinds,12 due to the high costs, long
timescales, and valuable output of pharmaceutical research and development. The average cost of a novel drug that suc-
ceeds in clinical trials and reaches the market is $2.6B.13 This cost is driven by the high failure rate in the R&D process;
only 4% of drug discovery projects result in a marketed drug, and only 12% of candidate drugs that enter expensive and
time-consuming clinical trials reach the market.14 However, the value of an efficacious drug to a patient whose disease
is cured or ameliorated may be incalculable, and the associated financial benefit to a pharmaceutical company can be
commensurately large; a “blockbuster” drug will achieve sales measured in billions of dollars per year.
The low success rate of pharmaceutical R&D is, in large part, due to the complexity of the process and the ultimate goal.
Drug discovery begins with a biological target implicated in a disease process. This is typically a protein involved in a bio-
logical pathway which, if inhibited or stimulated, will treat the disease; for example, inhibiting an essential protein in bacte-
ria, thereby killing the organism, can result in an antibiotic, while stimulating the dopamine receptor in the brain can treat
the symptoms of Parkinson's disease. Once a suitable target has been identified, the objective of a drug discovery project is
to identify a therapeutic that will achieve the desired effect on the target when dosed to a patient, while avoiding serious
side effects. This process often begins by finding initial “hits” that show activity against the target in an in vitro assay, which
is followed by an iterative optimization process in which new chemical compounds are synthesized and tested to identify a
candidate drug suitable for clinical trials. The design of a high-quality clinical candidate is a complex process, requiring
multi-parameter optimization (MPO) of target activity and many other characteristics required in an efficacious and safe
drug, often summarized as absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. As com-
pounds progress through the drug discovery process, more complex and expensive experiments are used to assess their like-
lihoods of success as a drug before a candidate is chosen for clinical trials in humans, subject to approval by the regulatory
authorities. The drug discovery process, from selection of a target to nomination of a clinical candidate, takes an average
5.5 years, and the complete R&D process through to launch of a new drug takes 13.5 years on average.14
Clearly, the abilities to make accurate predictions of the best compounds to synthesize and which to progress to
more expensive studies, based on initial experimental results, has the potential to dramatically improve the cost, time,
and success rate of drug discovery. These objectives are challenging due to the nature of the data available with which
to build predictive models. Datasets are typically much smaller and sparser than those seen in traditional machine
learning applications, such as image recognition and language processing. It is rare for a compound to have been mea-
sured in all relevant experiments, and no experiments are run on all potential compounds of interest. In a typical phar-
maceutical company's database, less than 1% of the possible experimental data points across all compounds of interest
will have been measured. In addition to sparsity issues, drug discovery data contain a high degree of experimental noise
due to the variability inherent in biological assays.7 Even when sources of experimental variability are minimized, the
results for a given compound in an experimental assay will often vary by 0.5 log units.15
A wide range of machine learning methods has been applied to predict compound activities and ADMET proper-
ties.16 These quantitative structure-activity relationship (QSAR) models relate features calculated from chemical struc-
tures (often referred to as “descriptors”) to one or more target activities or ADMET properties. A comparison of deep
learning imputation with the broader field of machine learning in the context of drug discovery is given by Irwin et al.7
A successful implementation is the Alchemite method,1-5 which has outperformed other data imputation techniques
both in terms of accuracy and modeling performance8 as well as flexibility of implementation and robustness to the
challenges associated with practical drug discovery applications.7
Alchemite demonstrated qualitative benefits over a variety of other machine learning methods, including random
forests (RFs),17 deep neural networks,18 matrix factorization,19,20 and purpose-made drug discovery imputation rou-
tines21,22 on two benchmark drug discovery datasets.6 These homogeneous datasets—purely comprised of target
activities—were also designed to mimic the challenging extrapolation expected in drug discovery applications, where
the training set is “known chemistry,” and the test set requires extrapolation into “new chemistry” that has not yet been
seen by the models.22 This application also saw the ability for uncertainty estimates given by Alchemite to allow sub-
stantial enhancements to the predictive quality of models. By exploiting the bespoke uncertainty estimate for each
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prediction and focusing in on the most confident predictions, the effective accuracy of models exceeded a coefficient of
determination (R2) of 0.9, compared to the headline figure of 0.44 on the entire dataset.6,8 This focusing effect is impos-
sible for methods which do not provide a robust error bar for each individual prediction,8 and would not yield a benefit
where the error bars are of low quality.
The Alchemite method proved more robust than a suite of standard machine learning methods when applied to a
real and active drug discovery project.7 This application demonstrated that—in addition to coping with noise and
sparsity—Alchemite could address temporal evolution within datasets and included a mixture of heterogeneous end-
points in a single model. These endpoints can either be unrelated, in which case they are treated separately, or related
through complex functions of multiple experimental measurements. These benefits of deep imputation were retained
on the small-scale datasets typical of a drug discovery project, in contrast with many deep learning methods that rely
on large-scale datasets to gain value over simpler machine learning methods in this field.
The method also successfully assisted in finding a novel, active anti-malarial compound when combined with gener-
ative methods.8-10,23 This application relied on a so-called “virtual” models,8 which depend only on calculated molecu-
lar descriptors, allowing virtual screening of the generated compounds, which had not yet been synthesized or tested
experimentally. The use of Alchemite's robust uncertainty estimates in combination with probabilistic MPO tech-
niques24 enabled the confident selection of a compound for synthesis and experimental validation.
The abovereported successes have all, to date, been achieved on small to moderately sized datasets. For typical drug
discovery projects, this would mean hundreds to a few thousand compounds (rows), and tens of experimental endpoints
(columns) in the data matrix.7 While the Alchemite method has fulfilled the criteria for a robust and practically useful
methodology to tackle challenging applications in the field of drug discovery,7 a key requirement is to prove the scalability
of the method to large datasets,8 comparable in scale to data available to a moderate-to-large pharmaceutical company.
Such a “large” dataset would contain of order one million compounds and thousands of experimental endpoints.
Scalability has been the focus of other imputation methods, such as the MACAU matrix factorization method,19
which in order to achieve scalability to millions of compounds as desired, results in a linear model which will only cap-
ture a shallow degree of the correlation between endpoints.8 In contrast to this, the Alchemite method presents a
nonlinear deep learning methodology, which has provably exploited multiple experimental correlations to predict com-
plex and multifactorial cell-based properties.
Application to large-scale databases of compound data will bring further benefits. Learning from interassay correla-
tions across much larger numbers of compounds than would be explored in a single project will enable this information
to be leveraged across multiple drug discovery projects and biological targets. This will improve the accuracy of predic-
tions and may reveal unexpected historical correlations between experimental endpoints. Virtual models derived from
such a “global” model will improve the virtual screening of new compounds. Imputation of new activities for existing
compounds may reveal opportunities for repurposing compounds for different therapeutic objectives. These applica-
tions will unlock enormous value from the wealth of data stored in pharmaceutical companies' data repositories, but
whose full potential is, as yet, unrealized. Furthermore, achieving these objectives with a single multitarget model
across all compounds and endpoints will reduce computational complexity and cost, vs building and updating models
for individual projects on an ad hoc basis.
In this work, we show the first successful application of the Alchemite deep imputation methodology to a pharma-
scale dataset within a reasonable computational cost. This important step demonstrates that the method meets the
requirements for implementation as an overarching modeling method to realize the benefits outlined above. To evalu-
ate the algorithm's ability to successfully handle different kinds of data on the large-scale dataset used in this work, we
considered three relevant drug discovery applications:
• Project activities: In a drug discovery project, compounds are assessed using assays to test for activity against one or
more biological targets. The Project Activities endpoints were used to evaluate the ability to prospectively predict the
activities (measured as the concentration at which half of the maximum inhibition is observed, IC50) of compounds
against targets. The data are aggregated across many drug discovery projects, and therefore there are 178 different
target columns, each corresponding to a distinct IC50.
• ADMET: This dataset was used to evaluate the ability to predict a broad range of ADMET endpoints, including com-
pound solubility and cell permeability, the extent that compounds inhibit common drug-metabolizing enzymes, met-
abolic stability, and toxicity endpoints. For ADMET endpoints that describe activities against known common
ADMET targets, the column data type is either an IC50, or one or more percentage inhibition (%inh) results at differ-
ent concentrations, but never both together.
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• High-throughput screening (HTS): At the inception of a drug discovery project, initial chemical starting points may
be identified by a broad and coarse sweep of a wide diversity of compounds to identify those that show indications of
activity against the target in question. These HTS campaigns may test hundreds of thousands, or even millions,
of compounds. To achieve this at an acceptable cost and time, high-throughput assays are employed that are often
noisier than the later project activity assays. The majority of data points will also show little or no activity, which cre-
ates a significant bias in the resulting dataset. The objective of this application was to assess the ability to predict
HTS activities, despite the limitations in these data. In particular, we wished to test the ability of Alchemite models
to predict the activities of a full HTS screen (Assay X) from the results of a much smaller pilot screen. These columns
are usually either an IC50, (sometimes with a single high concentration %inh result), or multiple %inh results mea-
sured at different concentrations.
In order to allow reproducible comparison of our results, we also include the latest performance of the Alchemite
algorithm on a publicly available dataset. The data cover 159 sparse kinase assays downloaded from ChEMBL,25 and
were assembled by Martin et al.22 This dataset was used in a previous benchmarking study,6 and the results reported
here are the most recent, from an improved version of the Alchemite algorithm.
METHODS
The deep imputation method used in this work, Alchemite, is based on the iterative application of a deep learning algo-
rithm to the sparse experimental data to identify and leverage nonlinear correlations between endpoints. It has been
previously described in detail in Verpoort et al26 and its application to drug discovery data was described in References
6 and 7. A full description of the method is also included in the “Methods” section of the Supplementary Information.
Here, we will provide a high-level summary of the method.
Two classes of model are used in this work:
• Imputation: These models generate predictions for the test data points using sparse assay data as input, in addition to
molecular descriptors, and test an Alchemite model's ability to “fill in the gaps” in the experimental data for com-
pounds that have been synthesized and tested in some assays.
• Virtual: These models are built to expect only molecular descriptors as input. They test an Alchemite model's ability
to make predictions based only on compound structure, that is, for a compound that has not yet been synthesized or
tested.
To train an imputation model, missing values in the sparse experimental data are first given provisional estimates of
numbers drawn from a distribution approximating that of the existent experimental data for each endpoint. For each
of the N endpoints, the other N  1 endpoints and the structural descriptors are used to build models of the experimen-
tal data in the endpoint, and this model is used to impute updated values for the initially missing data for each endpoint
in parallel to obtain improved estimates for each missing value. This procedure is then iterated, using the estimates
from iteration I  1 to generate the Ith set of estimates. Once the estimates are sufficiently converged, or the desired
number of iterations has been carried out (typically two or three iterations), the algorithm returns the latest set of esti-
mates as the predictions for all missing values in the dataset.
The virtual model is trained similarly, except that the model is constrained not to use experimental endpoints as
inputs in the first iteration, mimicking the later application to virtual compounds. This approach still leverages
nonlinear correlations between endpoints through the later steps of the iterative procedure, enabling improvements in
performance over methods that simplify focus on predicting one endpoint at a time. Predictions can then be made tak-
ing as input the chemical descriptors of a compound and iteratively generating estimates for every endpoint, and
returning the latest set of consistent estimates.
For both imputation and virtual models, the underlying modeling of each endpoint is performed using a proprietary
“gradient” kernel. In contrast to standard neural network sigmoid or rectifier activation functions, which can be envis-
aged as beginning with a large-length-scale approximation of a function and gradually adding more fine detail, the gra-
dient kernel begins with detailed local models and gradually stitches them together into a cohesive whole. This enables
more accurate capture of effects like activity cliffs—where a response rapidly varies as a function of the inputs—and is
generally on the order of a thousand times quicker to train due to the inherent parallelizability.
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One of the most important elements of the deep imputation model is the ability to quantify the uncertainty in pre-
dictions. This enables one to separate the most confident predictions from uncertain predictions, targeting future
resources only on those compounds with the highest probability of success. An ensemble of submodels is used to quan-
tify uncertainty for each endpoint at each iteration. Each submodel is trained on a bootstrap sample of the available
data to provide accurate treatment of the variation within the data.
One additional complexity of the drug discovery data used here is that multiple endpoints are frequently measured
in the same experimental assay. For example, permeability assays often report both apical (Papp A to B) and basolateral
(Papp B to A) permeability endpoints, as well as the ratio (B to A)/(A to B). Because the ratio depends directly on the
two values, the apical and basolateral values should not be used as inputs to predict the ratio. Therefore, in general one
endpoint from a given assay should therefore not be used as input to predict another endpoint from the same assay, as
at test time either both endpoints will have been measured for a given compound or neither will be available. To cap-
ture this, Alchemite includes generalized, asymmetric constraints on column dependencies. These can also be used to
ensure assays that are typically run late in a program are not used as input to predict assays run earlier for a given com-
pound (while still allowing the early stage assays to be used as input to predict the late-stage assays).
COMPARISON QSAR MODELS
A RF model was also constructed for each individual endpoint as representative examples of QSAR methods. These RF models
were generated using the scikit-learn implementation of regression RF27 and take compound descriptors as input only.
A wider comparison of QSAR methods was previously undertaken for project data by Irwin et al.7 This included
partial least squares, RF, Gaussian process, and radial basis function models and found RF models to be broadly repre-
sentative of the accuracy of QSAR methods. Advanced (multitarget) methods such as deep neural networks and matrix
factorization were compared to Alchemite by Whitehead et al.6 In all cases, Alchemite's deep imputation method was
found to outperform the other approaches in each case significantly.
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where N is a number of compounds in the set, ypredi is the predicted value, and y
obs
i is the experimentally observed value
for data point i. The RMSE is expressed in the same units as the observed property values. R2 values were calculated
only for endpoints with greater than five data points to give sufficient statistical relevance.
DATASET
All modeling data in the main study are proprietary and were provided by Takeda Pharmaceutical Company Ltd. Prior
to modeling, all qualified and out-of-range data were removed. The remaining data were transformed into units more
amenable for machine learning (eg, log transformations were applied to columns which varied many orders of magni-
tude). To maintain full modeling rigor, the dataset was split into training, validation, and independent test sets. The full
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training dataset contained 678 994 compounds and 1166 experimental endpoints; the breakdown across the three appli-
cations described above is shown in Table 1.
The blind test set contained a total of 17 660 data points across endpoints for each application, as described in
Table 2.The independent, blind test sets were prepared by Takeda and withheld during the model building and internal
validation process. Predictions for the blind test sets were provided to Takeda before the experimentally observed values
were revealed. The test sets were generated by Takeda in the following ways:
• Project activities: The test data points were selected temporally, that is, the most recently measured data points were
withheld, to test the models' abilities to predict the activities of the most recently synthesized compounds and assay
results.
• ADMET: The test data points were selected randomly to test the models' abilities to predict ADMET properties for a
wide diversity of compounds. This selection method gives an even coverage of each type of endpoint and value
according to their prevalence in the overall dataset.
• HTS: A small proportion of the test data points were selected randomly. However, the majority were derived from a
single assay (Assay X), for which the results of a pilot screen were provided in the training set, but the results from
the remaining compounds in the full screening collection were withheld. The split was arranged in this way to test
whether the majority of a more detailed high throughput screen could be predicted using the very broad pilot screen.
ChEMBL kinase dataset
We provide results for a publicly available dataset which allows direct comparison with other methods. The data cover
159 sparse kinase assays downloaded from ChEMBL,25 and were assembled by Martin et al.22 The dataset is provided
with the Supplemental Information to this manuscript.
Compound descriptors
A total of 330 molecular descriptors were calculated with the StarDrop Auto-Modeller module for each compound.
These descriptors can be computed from the atom and bond graph structure of any compound, including virtual com-
pounds, and therefore all descriptors are present for each compound in the dataset. The set of 330 descriptors comprises
TABLE 1 The breakdown of the training data in terms of the three applications (project activities, high-throughput screening [HTS],
absorption, distribution, metabolism, elimination, and toxicity [ADMET]) and the number of endpoints, compounds, and data points, along
with a measure of sparsity
Application Number of endpoints Number of compounds Total number of data points Sparsity (% filled)
ChEMBL kinase 159 10 177 86 506 5.3
Project activities 178 4501 36 274 4.5
HTS 748 662 635 17 951 700 3.6
ADMET 240 30 495 117 097 1.6
TABLE 2 A summary of the number of test points for each dataset (project activities, high-throughput screening [HTS], absorption,
distribution, metabolism, elimination, and toxicity [ADMET]) and the selection strategy
Application Number of test points Selection strategy
ChEMBL kinase 27 811 Extrapolation, test set is outliers from clustering of data
Project activities 1167 Temporal, that is, most recently measured data points
HTS 10 396 7858 from a single HTS screen (Assay X), else random
ADMET 6097 Random
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common whole-molecule properties, including calculated lipophilicity, molecular weight, topological polar surface
area, and McGowan's volume, as well as counts of 300 chemical substructures defined as SMARTS patterns,28 which
are essentially regular expressions for chemical subgraph pattern queries.
RESULTS
Here, we show the results of the Alchemite models compared with RF models for each endpoint in the independent test
set. Because the data for each application represent a large number of endpoints, as shown in Table 1, we show a profile
of endpoint results, ordering the R2 values ordered from highest to lowest for each method (see Figure 1 for example).
Alchemite also provides uncertainty estimates for each prediction and we also present a comparison of the uncertainty
estimates with the observed errors for the independent test.
ChEMBL kinase test results
Figure 1 shows the profile of endpoint results for the independent test data for the ChEMBL kinase dataset. The median
R2 across the 159 columns in the test set is imputation: 0.48(2), virtual: 0.06(1), RF: 0.14(3). We can see that Alchemite
imputation is the highest, followed by Alchemite virtual. The median R2 for RF is negative, which means that more
than half of the columns have RF models that are worse than random (the variance in the predictions is larger than the
variance of the overall column).
Project activities test results
Figure 2 shows the profile over project activity endpoints for the independent test data. This plot includes curves show-
ing the performance of Alchemite Imputation and Virtual models relative to the RF models. The median R2 for the
Alchemite Imputation model is 0.69, compared to 0.28 for RF models. The median R2 for the Alchemite Virtual model
is 0.55 which is also substantially higher than the RF models, showing that the multitarget deep learning with sparse
experimental data trains a very high-quality virtual model.
Each of the points in the profile shown in Figure 2 is an R2 value for predictions of a different endpoint. In the case
of the project activity endpoints, these are all measurements of activity against a target. Scatter plots and uncertainty
analysis are given for a focused example in the Supplementary Information better to show how these predictions can be
used in practice, while inspecting the quality of the models and the uncertainty predictions.
FIGURE 1 Profile of the coefficient of determinations (R2) achieved on the validation set for kinase endpoints. The endpoints are
ordered from highest R2 (left) to lowest (right). Alchemite imputation model (orange), Alchemite virtual model (gray), and random forest
models (blue) are plotted for comparison
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ADMET test results
The results for the independent test set for the ADMET endpoints are shown in Figure 3, and we can see a similar trend
to the above example. The best model is the Alchemite Imputation model with a median R2 of 0.36, close behind is the
Alchemite Virtual model with a median R2 of 0.32 and finally, RF models achieve a median R2 of 0.19.
The ADMET endpoints represent a wide variety of different data types, and it is interesting to compare the profile of
results for different classes of ADMET endpoints. In particular, Figure 4 shows the accuracy profiles for pIC50 and
pEC50 (the negative base-10 logarithm of the concentration in Molar units which exhibits 50% of the maximum effect)
endpoints respectively. From these plots, one can see that the Alchemite models have a much larger advantage over RF
for the pEC50 endpoints than for pIC50 endpoints. The Alchemite imputation model outperforms the Alchemite virtual
model for the pEC50 endpoints, whereas the two models are roughly equivalent for pIC50 endpoints. This result is con-
sistent with those seen in smaller project datasets, where Alchemite tends to show the greatest benefit for complex,
multi-mechanistic endpoints.7 While a pIC50 measurement relates to the inhibition of a single target protein, pEC50
measurements result from more complex assays that may be influenced by multiple factors; for example, the activity of
a compound in a cell will relate not only to its activity against a target protein, but also permeability through the cell
membrane, solubility in the buffer solution and binding to other proteins in the cellular matrix. This demonstrates one
of Alchemite's advantages, namely the ability to learn directly from relationships between experimental endpoints,
which may capture these other factors, to make better predictions.
FIGURE 2 Profile of the coefficient of determinations (R2) achieved
on the independent test set for Project activity endpoints. The endpoints
are ordered from highest R2 (left) to lowest (right). Alchemite
imputation model (orange), Alchemite virtual model (gray), and
random forest models (blue), are plotted for comparison
FIGURE 3 Profile of the coefficient of determinations (R2) achieved
on the independent test set for absorption, distribution, metabolism,
elimination, and toxicity (ADMET) endpoints. The endpoints are
ordered from highest R2 (left) to lowest (right). Alchemite imputation
(orange), Alchemite virtual (gray), and random forest (blue) models are
plotted for comparison
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HTS test results
Figure 5 shows the profile of R2 results over the HTS endpoints in the independent test set. In this case, the Alchemite vir-
tual model is essentially equivalent to the RF models, whereas the Alchemite imputation results are an improvement. The
median R2 for RF is 0.23, similar to the Alchemite virtual model with a median R2 of 0.27, but lower than the Alchemite
imputation model, which achieved an R2 of 0.43. This shows that there is additional information in the correlations
between endpoints and in the structure of the training data that can be exploited by using Imputation on HTS data.
One objective of the HTS test was to assess the ability of the Alchemite models to predict activities for the full
screening deck for Assay X, based on the pilot screen data for this assay. However, none of the models considered in
this study showed sufficient predictive power for this endpoint, and the R2 values were close to zero (Alchemite imputa-
tion 0.07, Alchemite virtual 0.12, RF 0.17). There are several possible explanations for this:
• The overlap in compounds with data measured in Assay X and other endpoints in the training set is lower than is
typical for other endpoints in the training set. The maximum overlap corresponds to only 10% of the compounds for
Assay X.
FIGURE 4 Profile of the coefficient of determinations (R2) achieved on the independent test set for absorption, distribution,
metabolism, elimination, and toxicity (ADMET) pIC50 endpoints (left) and ADMET pEC50 endpoints (right). The endpoints are ordered
from highest R2 to lowest. Alchemite imputation model (orange), Alchemite virtual model (gray), and random forest models (blue) are
plotted for comparison
FIGURE 5 Profile of the coefficient of determinations (R2) achieved
on the independent test set for HTS endpoints. The endpoints are
ordered from highest R2 (left) to lowest (right). Alchemite imputation
model (orange), Alchemite virtual (gray), and random forest (blue)
models are plotted for comparison
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• The distribution of percentage inhibition data is challenging to model. For Assay X, the distribution is shown in
Figure 6. The large majority of the measured values are distributed around 0%, plus or minus 10% and only a very
small proportion of compounds are measured to have significant activities, as we would expect from HTS. Further-
more, the noise in the measured values for inactive compounds may be affecting the ability of the accuracy metric to
distinguish good from poor models and guide the model optimization. It may be possible to transform the percentage
inhibition data to reduce the impact of this noise.
In order to test the impact of the bias in the distribution of observed values, a new version of the model was built in
which the active data were oversampled by duplicating the active compounds 15 times relative to the inactive. This did
not improve the accuracy of the resulting model. This indicates that the problem is less likely to be due to sampling bias
and suggests that the algorithms may be attempting to model the noise in the data rather than the signal. If the com-
pound structures had been known, compound set enrichment would be an option to look for statistically significant sig-
nals relative to the of the HTS background distribution.29
Taking uncertainties in predictions into account
To test the accuracy of the uncertainty estimates produced by Alchemite, we can plot the RMSE in prediction vs the
most confidently predicted fraction of the test set, that is, smaller fractions correspond to the predictions with
the smallest error bars (according to the algorithm). If the uncertainties are conveying useful information, we would
expect the most confidently predicted fractions of the test set to show better accuracy, that is, a lower RMSE.
The quality of uncertainty predictions, averaged across all 159 ChEMBL kinase dataset endpoints, as a function of
the most confidently predicted fraction of the dataset, is shown in Figure 7. All of the ChEMBL kinase dataset end-
points are in the same units (pIC50, the negative base-10 logarithm of the concentration in molar units which exhibits
50% of the maximum target inhibition), and this average is well-defined. For comparison, the uncertainties in the RF
predictions were calculated as the standard deviation of predictions from the ensemble of decision trees. Figure 7 shows
that the error bars produced by all three methods, on average, provide some useful information in identifying more
accurate predictions. In addition, the absolute RMSE is much higher, on average, for RF predictions. The Alchemite vir-
tual model has a lower RMSE, and the imputation model has the best RMSE.
The quality of uncertainty predictions, averaged across all 178 project activity endpoints, as a function of the most
confidently predicted fraction of the dataset, is shown in Figure 8. All of the project activity endpoints are also in the
same units (pIC50). Figure 8 again shows that the error bars produced by all three methods, on average, provide some
useful information in identifying more accurate predictions. The interpretation of the plot is the same as that of
Figure 7. However, the benefit from RF error bars is much smaller than that of the Alchemite uncertainty estimates.
The decrease in RMSE correlates much more strongly with the error bars for both the virtual and imputation Alchemite
models. In addition, the absolute RMSE is much higher, on average, for RF predictions. The Alchemite virtual model
has a lower RMSE, and the imputation model has the best RMSE. An example of a similar analysis for an individual
project activity endpoint is provided in the Supplementary Information in Figures S3 and S4.
We can also explore the ability of Alchemite to focus on the most confident predicted values in the more heteroge-
neous ADMET endpoints. Unlike the project activity endpoints, the mixed units across the ADMET endpoints mean
FIGURE 6 The distribution of training values for Assay X. Most of
the values are centered around 0% inhibition, that is, inactive
compounds, and the width of that peak is likely to be noise
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that the error analysis cannot be summarized in a single graph for the full dataset in analogy to Figures 7 and 8. We
consider some illustrative examples of individual endpoints in Figures 9 and 10, with additional uncertainty quantifica-
tion plots shown in Figures S5 and S6 of the Supplementary Information. Figure 9 reflects the performance of
Alchemite permeability models—the logarithm of the basolateral to apical permeability in a cell line (Papp B to A)—by
comparing the most confident 50% of predictions with all predictions for both the imputation (left) and virtual (right)
models. The most confident predictions are more closely clustered to the identity line, and the clear outliers have been
dropped.
Figure 10 plots the predictions for an unrelated pEC50 endpoint and shows that, while the predictions for this end-
point follow the observed values quite well, there is more scatter in the predictions, and some points have large uncer-
tainty estimates. That is to say, predictions for this endpoint are accurate, but not precise. If more precision is required,
we can again focus in on the most confident predictions. In this instance, we show the most confident 25% of predic-
tions according to the Alchemite error bars, and these predictions are clustered around the identity line in a tighter
grouping than the baseline model.
FIGURE 7 Graph illustrating the relationship between confidence and accuracy of prediction for the ChEMBL kinase dataset test set.
The x-axis shows the most confidently-predicted fraction of the test data, that is, in moving from right to left only the most confidently
predicted values are included. The y-axis shows the root mean square error (RMSE) of the fraction of predictions, aggregated over
159 ChEMBL kinase dataset endpoints. A lower RMSE value indicates more accurate predictions. Results for random forest models are
shown in blue, the Alchemite imputation model in orange, and the Alchemite virtual model in gray. For ease of visualization, Gaussian
smoothing has been applied to the accuracy calculated at each sampled fraction
FIGURE 8 Graph illustrating the relationship between confidence
and accuracy of prediction for the project activities test set. The x-axis
shows the most confidently-predicted fraction of the test data, that is, in
moving from right to left only the most confidently predicted values are
included. The y-axis shows the root mean square error (RMSE) of the
fraction of predictions, aggregated over 178 project activity endpoints. A
lower RMSE value indicates more accurate predictions. Results for
random forest models are shown in blue, the Alchemite imputation
model in orange, and the Alchemite virtual model in gray. For ease of
visualization, Gaussian smoothing has been applied to the accuracy
calculated at each sampled fraction
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We can see that the correlation between the most confident and accurate results is also strong for these models,
even when the baseline R2 is not high. This importantly allows the models to be useful even in situations where they
would be otherwise discarded due to a poor correlation for the full test set. The correlations of RMSE with the confi-
dence in predictions data for these endpoints are shown Figures S5 and S6 in the Supplementary Information and show
a similar result to that of Figures 7 and 8. These confirm the benefits of quantifying uncertainty for diverse endpoints.
Computational resources
Depending on hyperparameters, it takes 8 to 16 hours to train this model on an AWS EC2 m5.4xlarge instance, (64 GiB
of Memory, 16 vCPUs). A larger cost is incurred for hyperparameter optimization, for which the time can be estimated
FIGURE 9 Scatter plots showing predicted vs observed values for all points in the independent test set for a for a single log permeability
(Papp B to A) absorption, distribution, metabolism, elimination, and toxicity (ADMET) endpoint. The Alchemite imputation model result is
shown in orange (left) and the virtual model in gray (right). Error bars are shown, corresponding to the Alchemite uncertainty estimate for
each point (1 SD). The most confident 50% of the predictions for each model, according to the associated Alchemite uncertainty estimates,
are highlighted as bold points. The identity line is shown for comparison (dashed)
FIGURE 10 Scatter plots showing the predicted vs observed values for all points in the independent test set for a single pEC50
absorption, distribution, metabolism, elimination, and toxicity (ADMET) endpoint. The Alchemite imputation model result is shown in
orange (left) and the virtual model in gray (right). Error bars are shown, corresponding to the Alchemite uncertainty estimate for each point
(1 SD). The most confident 25% of the predictions for each model, according to the associated Alchemite uncertainty estimates, are
highlighted as bold points. The identity line is shown for comparison (dashed)
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as Thyp≈ 1.3NfoldNsamplesTbase, where Tbase is the base training time for a dataset, Nsamples is the number of hyper-
parameter optimization samples required for convergence (usually 20-50), and Nfold is the number of cross-validation
folds. However, following an initial hyperparameter optimization, the model can be updated with new data in the time
taken for training, unless there is a significant change in the overall structure of the dataset. Furthermore, the hyper-
parameter optimization process can be further parallelized over the cross-validation folds to reduce the overall time by
a factor of Nfold.
CONCLUSIONS
Some general conclusions can be drawn across all applications. Alchemite imputation models consistently outperform
RF models, and generally outperform Alchemite virtual models. This highlights a benefit of deep learning imputation,
which can learn directly from the relationships between experimental endpoints and gain valuable information, even
from very limited experimental data, to more accurately fill in missing experimental values. In all applications, the
Alchemite virtual model performed better than or equivalently to RF. The Alchemite algorithm is competitively fast
when compared to other deep learning methods and was applied to a pharma-scale dataset within a reasonable
computational cost.
We have demonstrated that the Alchemite uncertainty estimates correlate strongly with the accuracy of the
corresponding predictions, unlike those derived from RF ensemble-based uncertainties. This result is particularly
exciting because generating robust and objectively useful uncertainty estimates from neural networks remains a
major challenge.30 Valid uncertainty estimates are essential to the effective use of models; understanding where a
result is likely to be sufficiently accurate enables high-quality compounds to be identified with confidence while
avoiding missed opportunities by incorrectly discarding a potentially good compound due to an uncertain
prediction.15
There were endpoints which could not be modeled by any method for all applications (ie, the rightmost points in
Figures 1-5). Without heavy preprocessing, all large datasets will have such endpoints, especially on the repository-wide
scale. We should not expect to be able to model all endpoints, particularly when the data are noisy or where few data
points are available. However, it is notable that the inclusion of noisy and uncorrelated endpoints in the dataset did not
have a detrimental effect on the performance of the Alchemite models for the majority of endpoints. This contrasts with
other multitarget modeling approaches that benefit where there are strong correlations between endpoints, but suffer a
detrimental effect from the introduction of uncorrelated endpoints into the dataset.31
There are also some more specific conclusions we can draw for each of the three individual applications.
Project activities conclusions
For the project activity endpoints, all of the Alchemite models significantly outperform RF, showing the method is very
effective on activity type endpoints. The results from the independent test were consistent with those from the internal
validation; this is remarkable because the test set selected by Takeda Pharmaceuticals was temporally based, rep-
resenting the most relevant and recent compounds in the corresponding project endpoints. Therefore, the results indi-
cate the consistency and utility one could expect when deploying Alchemite models in real projects.
As expected, the Alchemite imputation model slightly outperforms the virtual model because the former model has
access to more information, in the form of sparse experimental data. This shows that the cross-correlations between
experimental endpoints offer significant practical utility, and it is sensible to exploit this where possible.
HTS conclusions
The Alchemite imputation model outperforms the Alchemite virtual and RF models on HTS data, which represent
some of the most challenging and noisy data. However, the prediction of the full screening collection for “Assay X”
based on an initial pilot screen was not possible with any of the models. One approach to addressing this may be to
apply a classification method, but this is beyond the scope of this study.
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ADMET conclusions
For ADMET endpoints, both Alchemite imputation and virtual models outperform RF on the full dataset, and the
imputation model achieves higher accuracies than the virtual model. Individual ADMET endpoints are less likely to
correlate, as the different endpoints are often quite distinct, and therefore we see a smaller improvement of the
Alchemite imputation model over the Alchemite virtual model and RF. However, more complex experimental end-
points often depend on multiple factors that may be captured by endpoints derived from simpler assays, and, in these
cases, we see a more substantial improvement of the Alchemite models over conventional QSAR methods such as
RF. This represents a sizeable potential value because the simpler assays are typically lower cost and higher throughput
than the more complex, cell-based assays and hence are often used earlier in a drug discovery project. Imputation can
better leverage the results from these earlier assays to more accurately select the best compounds for more expensive,
downstream studies.
We note that endpoints derived from the same experimental assay are not used as input to predict one another in
this study. However, in this study, we have taken a very conservative approach to constrain the dependencies between
assay endpoints; for example, endpoints that are not necessarily measured together, such as solubility measurements at
different pH values, have also been constrained not to impute one another. This does not need to be the case; solubil-
ities measured at different pH values could be defined as independent inputs, allowing solubilities at 1 pH value to be
used to predict solubilities measured at different pH values. We would expect the use of such related, but independent
endpoints to further improve the accuracy of the Alchemite models. Such a use could, for example, enable accurate pre-
diction of solubilities at multiple pH values to be made based on a single measurement, further reducing the experimen-
tal resources required.
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